Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Dec 26.
doi: 10.1007/s40292-025-00777-y. Online ahead of print.

Comprehensive Review on Febuxostat for Hyperuricemia with Gout: Insights from Current Practice and Clinical Trials

Claudio Borghi  1   2 , Federica Piani  3 , Athanasios L Manolis  4
Affiliations
Review

Comprehensive Review on Febuxostat for Hyperuricemia with Gout: Insights from Current Practice and Clinical Trials

Claudio Borghi et al. High Blood Press Cardiovasc Prev. .

Abstract

Hyperuricemia is a metabolic disorder associated with an increased risk of gout, chronic kidney disease (CKD), and cardiovascular disease (CVD). The management of hyperuricemia in conditions where urate deposition has already occurred primarily relies on xanthine oxidase inhibitors (XOIs), such as allopurinol and Febuxostat. Febuxostat, a non-purine selective XOI, has demonstrated superior urate-lowering efficacy, particularly in patients with renal impairment. This review provides an in-depth analysis of Febuxostat's pharmacological properties, clinical efficacy, and safety profile, with a focus on cardiovascular and nephroprotective effects.

Keywords: Cardiovascular disease; Febuxostat; Uric acid; Xantine oxidase inhibitors.

PubMed Disclaimer

Conflict of interest statement

Declarations. Conflict of interest: On behalf of all authors, the corresponding author states that there is no conflict of interest. Ethical Approval: This article is a review and does not contain any studies with human participants or animals performed by any of the authors. Therefore, ethical approval was not required. Consent to Participate: This article does not contain any studies with human participants or animals performed by the authors. All cited studies are properly referenced and comply with ethical standards as reported by their respective authors.

References

    1. FitzGerald JD, Dalbeth N, Mikuls T, Brignardello-Petersen R, Guyatt G, Abeles AM, et al. 2020 American college of rheumatology guideline for the management of gout. Arthritis Care Res (Hoboken). 2020;72(6):744–60. - DOI - PubMed
    1. Bardin T, Richette P. Definition of hyperuricemia and gouty conditions. Curr Opin Rheumatol. 2014;26(2):186–91. - DOI - PubMed
    1. Kuwabara M, Hisatome I, Ae R, Kosami K, Aoki Y, Andres-Hernando A, et al. Hyperuricemia, A new cardiovascular risk. Nutr Metab Cardiovasc Dis. 2025;35(3):103796. - DOI - PubMed
    1. Kuwabara M, Kodama T, Ae R, Kanbay M, Andres-Hernando A, Borghi C, et al. Update in uric acid, hypertension, and cardiovascular diseases. Hypertens Res. 2023;46(7):1714–26. - DOI - PubMed
    1. Cicero AFG, Kuwabara M, Johnson R, Bove M, Fogacci F, Rosticci M, Giovannini M, D’Addato S, Borghi C, Brisighella Heart Study group. LDL-oxidation, serum uric acid, kidney function and pulse-wave velocity: data from the Brisighella heart study cohort. Int J Cardiol. 2018;261:204–8. https://doi.org/10.1016/j.ijcard.2018.03.077 . - DOI - PubMed

LinkOut - more resources